CellChorus Inc., the leader in applying artificial intelligence to visually evaluate how cells perform and interact over time, announced the appointment of Andrew Last, PhD, to its board of directors.
Dr. Last brings more than three decades worth of experience leading a variety of life sciences organizations
HOUSTON, Texas — November 28, 2023 — CellChorus Inc., the leader in applying artificial intelligence to visually evaluate how cells perform and interact over time, announced the appointment of Andrew Last, PhD, to its board of directors.
Dr. Last brings more than three decades of experience leading global life sciences businesses to advise the CellChorus team as it grows the TIMING™ franchise. He currently serves as Executive Vice President and Chief Operating Officer of Bio-Rad Laboratories (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products with nearly $3 billion in revenue.
Dr. Last previously served as Chief Commercial Officer at Berkeley Lights. Prior to that he was Chief Operating Officer at both Intrexon Corporation and Affymetrix. Dr. Last has also held senior positions with Becton, Dickinson and Company; Applied Biosystems; Incyte Genomics; and Monsanto Company. He holds a PhD with Agrochemical Specialization and an MS in Bio-Aeronautics from Cranfield University, UK, as well as a BS from the University of Leicester, UK.
“Andy has had a front seat at some of the most exciting scientific and commercial advances in life sciences over the past several decades,” said Daniel Meyer, CEO of CellChorus. “We are thrilled to have his guidance as CellChorus advances the next frontier of single-cell analysis to provide scientists with a comprehensive understanding of how their cells interact and perform.”
About CellChorus
CellChorus® is the leader in applying artificial intelligence (AI) to visually evaluate how thousands of individual immune cells, such as T cells and NK cells, perform over time. The company applies Time lapse Imaging Microscopy in Nanowell Grids (TIMING™) with neural network-based AI to identify cells and evaluate their activity, including how they move, activate, kill and survive. The patent-protected CellChorus platform can link TIMING data and insights with information from other analysis modalities such as single-cell RNA sequencing and flow cytometry to provide a comprehensive understanding of cellular function, state and phenotype for the life sciences industry. Please visit cellchorus.com for more information.
Company Contact:
Daniel Meyer
Chief Executive Officer
CellChorus Inc.
TIMING@cellchorus.com